Literature DB >> 15958128

Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy.

David Allen1, Konstantinos Giannopoulos, Ian Gray, Norman Gregson, Anna Makowska, Jane Pritchard, Richard A C Hughes.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired disorder of the peripheral nervous system with a probable auto-immune pathogenesis. The nature of the responsible autoantigens is unclear in most patients. We used the Western immunoblot technique to seek antibodies to peripheral nerve protein antigens. Sera from eight of 32 (25%) CIDP patients, 12 of 37 (32%) Guillain-Barré syndrome (GBS) patients, zero of 30 (0%) chronic idiopathic axonal polyneuropathy patients and two of 39 (5%) healthy control subjects contained anti-peripheral nerve protein antibodies. The frequency of such antibodies was significantly greater in both CIDP (p = 0.04) and GBS (p = 0.003) patients than in normal control subjects. For CIDP patients, there were non-significant trends for antibodies to be more common in females and in those who responded to treatment with either intravenous immunoglobulin or plasma exchange. The commonest antibodies were directed against a band at 28 kDa, resembling that labelled by a monoclonal antibody against myelin protein zero (P0). Six CIDP and seven GBS patients' sera reacted with this band. These results support the view that antibodies to myelin proteins, and especially P0, are present in the serum of some patients with CIDP and GBS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958128     DOI: 10.1111/j.1085-9489.2005.0010207.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  16 in total

Review 1.  Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies.

Authors:  Jolien Wolbert; Mandy I Cheng; Gerd Meyer zu Horste; Maureen A Su
Journal:  JCI Insight       Date:  2020-02-13

2.  Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.

Authors:  H R Inglis; P A Csurhes; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-08       Impact factor: 10.154

3.  Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy.

Authors:  Maureen A Su; Dan Davini; Philip Cheng; Karen Giang; Una Fan; Jason J DeVoss; Kellsey P A Johannes; Lorelei Taylor; Anthony K Shum; Mariella Valenzise; Antonella Meloni; Helene Bour-Jordan; Mark S Anderson
Journal:  J Immunol       Date:  2012-04-06       Impact factor: 5.422

4.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

5.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

6.  Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice.

Authors:  Phillipe D O'Brien; Junguk Hur; Nicholas J Robell; John M Hayes; Stacey A Sakowski; Eva L Feldman
Journal:  J Diabetes Complications       Date:  2015-10-03       Impact factor: 2.852

Review 7.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 8.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

9.  A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.

Authors:  Cédric Louvet; Beniwende G Kabre; Dan W Davini; Nicolas Martinier; Maureen A Su; Jason J DeVoss; Wendy L Rosenthal; Mark S Anderson; Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2009-02-16       Impact factor: 14.307

Review 10.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.